Keyword: Tremfya (guselkumab)
Calling all digital entrepreneurs: Johnson & Johnson is looking for creative tech skincare solutions in its Digital Beauty QuickFire Challenge.
Novartis published 5-year data for Cosentyx showing long-term skin clearance in psoriasis patients.
Heads up, Novartis, Eli Lilly and Valeant: With guselkumab's Thursday nod, you’ve got company in the next-gen psoriasis space.
Novartis has some new data in hand that could set psoriasis med Cosentyx apart from its new competitors—big-time.